Abstract: Objective  To systematically review about RCTs clinical studies related to tirofiban in treatment of acute ischemic stroke(AIS), and to evaluate its efficacy and safety for AIS. Methods  Databases, such as Cochrane Library, EmBase, PubMed, SCI, WF, CNKI, VIP, and CBM were searched to collect all RCTs relevant to the tirofiban in the treatment of AIS. Then, the related data were extracted from the trials. Results  A total of 15 RCT clinical studies involving 1 266  patients were selected. The meta analysis showed that NIHSS of the AIS patients treated with tirofiban was lower than that of control group which was not treated with tirofiban (MD=1.31,  95%CI=1.011.62, I2=0%, P<0.01). The subgroup analysis revealed that NIHSS was lower than that of control group after 7 days of treatment(MD=1.39,  95%CI=0.732.04, P<0.01) and the result did not change after 14 days (MD=1.31,  95%CI=0.961.66, P<0.01). The BI score was higher than that of control group (MD=5.74, 95%CI=3.587.90, I2=0%, P<0.01). The MRS score was lower than that of control group (RR=2.09, 95%CI=1.522.87, I2=36%,  P<0.01). And the ADL score was higher than that of control group (MD=4.26, 95%CI=2.186.34, I2=18%, P=0.0001). Conclusion  Tirofiban was beneficial to the improvement of neurological deficit in the treatment of AIS patients.

Key words: tirofiban, cerebrovascular accident, system review, metaanalysis